🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Neuland Laboratories Limited NEULANDLAB NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.neulandlabs.com
Company Profile ↓
₹18,975.00
+46.47% 1Y
Mkt Cap₹24,344.71 Cr
P/E48.91
P/B14.30
Div. Yield0.16%
52W High₹23,995.00
52W Low₹11,533.68
Book Value₹1,461.02
EPS (TTM)₹387.97

Company Overview

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.4%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 22.9%.

Consistent Profit Growth

Net profit has compounded at 30.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 18.5% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 21.0%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Recent Developments

  • Mar 2026 Revenue of ₹1,932.12 Cr (+34.7% YoY); net profit ₹364.00 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +119.2%, earnings +962.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.5%, profit CAGR 30.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.51%
1 Year:119.20%

Compounded Profit Growth

5 Years:30.57%
1 Year:962.80%

Stock Price Performance

1 Year:+46.47%
6 Months:+31.97%
3 Months:+2.95%
1 Month:-16.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 60% of range
₹11,533.68 ₹23,995.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)19.93 · Oversold
Price Performance
1M-16.92%
3M+2.95%
6M+31.97%
1Y+46.47%
Valuation vs Sector

P/E of 48.91 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 22.9%.
  • Excellent profit margin of 21.0%.
  • Compounding revenue at 18.5% over 5 years.
  • Profit CAGR of 30.6% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • RSI at 20 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
48.91
Industry PE
36.43
Forward P/E
39.09
PEG Ratio
-
Book Value
₹1,461.02
Price to Book
14.30
P/S
11.30
EV/EBITDA
36.03
Dividend Yield
0.16%

Growth (CAGR)

Revenue 5Y
18.51%
Profit 5Y
30.57%
Revenue (YoY)
119.20%
Earnings (YoY)
962.80%

Profitability & Returns

ROCE
22.87%
ROE
19.42%
ROA
12.42%
Profit Margin
20.99%
Op Margin
30.60%
Gross Margin
55.17%
EPS (Latest Qtr)
₹115.10
EPS (TTM)
₹387.97

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
0.68
Current Ratio
1.42
Debt
₹301.27 Cr
Total Assets
₹2,930.14 Cr
Current Assets
₹1,483.13 Cr
Working Capital
₹772.93 Cr

Ownership

Promoter Holding
37.74%
Chg in Prom Hold
-0.02%
FII / Inst Holding
28.13%
Chg in FII Hold
-0.05%

Financial Snapshot

Enterprise Value
₹24,344.71 Cr
Total Revenue (TTM)
₹2,371.81 Cr
EBITDA
₹754.57 Cr
Free Cash Flow
₹-50.45 Cr
Operating Cash Flow
₹346.68 Cr
Shares Outstanding
₹1.28 Cr
Gross Margin
55.17%
Payout Ratio
3.09%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NEULANDLAB Neuland Laboratories Limited NIFTY_SMALLNSEPHARMA 18,975.00 48.91 ₹24,344.71 Cr 0.16% 22.87% 19.42% 18.51% 30.57%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 407.00 Cr363.00 Cr418.00 Cr393.00 Cr385.00 Cr440.00 Cr311.00 Cr398.00 Cr-292.75 Cr514.27 Cr439.71 Cr776.25 Cr641.58 Cr
Cost of Revenue ---------152.92 Cr229.57 Cr243.62 Cr321.01 Cr268.96 Cr
Gross Profit ---------139.83 Cr284.71 Cr196.09 Cr455.24 Cr372.62 Cr
Operating Expenses 287.00 Cr266.00 Cr280.00 Cr272.00 Cr278.00 Cr316.00 Cr249.00 Cr311.00 Cr-125.53 Cr151.70 Cr142.88 Cr173.00 Cr176.29 Cr
Operating Income 107.00 Cr83.00 Cr122.00 Cr106.00 Cr91.00 Cr107.00 Cr46.00 Cr71.00 Cr-14.30 Cr133.00 Cr53.21 Cr282.24 Cr196.33 Cr
EBITDA 120.00 Cr97.00 Cr137.00 Cr121.00 Cr107.00 Cr123.00 Cr62.00 Cr87.00 Cr-42.34 Cr157.35 Cr85.19 Cr319.79 Cr231.38 Cr
Interest Expense 4.00 Cr2.00 Cr4.00 Cr4.00 Cr4.00 Cr3.00 Cr1.00 Cr2.00 Cr-4.58 Cr5.37 Cr6.79 Cr7.21 Cr6.97 Cr
Pretax Income 110.00 Cr83.00 Cr122.00 Cr104.00 Cr92.00 Cr130.00 Cr49.00 Cr128.00 Cr-17.57 Cr129.44 Cr54.48 Cr287.49 Cr197.85 Cr
Tax Provision 25.30 Cr21.58 Cr32.94 Cr22.88 Cr24.84 Cr32.50 Cr16.66 Cr25.60 Cr-3.67 Cr32.58 Cr13.90 Cr74.82 Cr50.17 Cr
Net Income 85.00 Cr62.00 Cr89.00 Cr81.00 Cr68.00 Cr98.00 Cr33.00 Cr102.00 Cr-13.90 Cr96.85 Cr40.57 Cr212.67 Cr147.67 Cr
Diluted EPS 65.8948.2369.5663.4452.6676.2825.6079.18-10.8375.4931.62165.76115.10

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 469.00 Cr510.00 Cr579.00 Cr527.00 Cr667.00 Cr763.00 Cr937.00 Cr-1,160.90 Cr1,515.66 Cr1,434.38 Cr1,932.12 Cr
Cost of Revenue --------613.79 Cr733.80 Cr750.51 Cr947.12 Cr
Gross Profit --------547.11 Cr781.87 Cr683.87 Cr985.00 Cr
Operating Expenses 402.00 Cr430.00 Cr472.00 Cr477.00 Cr608.00 Cr661.00 Cr790.00 Cr-312.77 Cr374.48 Cr417.30 Cr494.98 Cr
Operating Income 52.00 Cr64.00 Cr87.00 Cr29.00 Cr32.00 Cr71.00 Cr107.00 Cr-234.34 Cr407.38 Cr266.58 Cr490.02 Cr
EBITDA 67.00 Cr80.00 Cr106.00 Cr51.00 Cr58.00 Cr102.00 Cr147.00 Cr-278.93 Cr472.21 Cr417.67 Cr599.41 Cr
Interest Expense 27.00 Cr24.00 Cr21.00 Cr19.00 Cr16.00 Cr22.00 Cr18.00 Cr-10.40 Cr11.07 Cr5.79 Cr18.70 Cr
Pretax Income 25.00 Cr42.00 Cr67.00 Cr14.00 Cr20.00 Cr53.00 Cr105.00 Cr-215.75 Cr401.44 Cr346.33 Cr488.98 Cr
Tax Provision 9.00 Cr15.12 Cr20.10 Cr1.82 Cr3.80 Cr36.57 Cr24.15 Cr-52.23 Cr101.36 Cr86.22 Cr124.98 Cr
Net Income 16.00 Cr27.00 Cr47.00 Cr12.00 Cr16.00 Cr16.00 Cr81.00 Cr-163.52 Cr300.08 Cr260.11 Cr364.00 Cr
Diluted EPS 17.9630.7552.7413.5712.8112.6362.85-127.45233.89202.74283.71

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 512.00 Cr524.00 Cr886.00 Cr1,071.00 Cr1,130.00 Cr1,231.00 Cr1,325.00 Cr-1,579.76 Cr1,832.56 Cr2,179.88 Cr2,930.14 Cr
Current Assets --------760.89 Cr921.08 Cr1,139.50 Cr1,483.13 Cr
Cash & Equivalents --------45.42 Cr87.58 Cr131.93 Cr76.67 Cr
Inventory --------279.23 Cr350.42 Cr385.76 Cr510.29 Cr
Receivables --------361.77 Cr373.53 Cr315.72 Cr541.35 Cr
Total Liabilities --------585.67 Cr549.86 Cr655.08 Cr1,055.66 Cr
Current Liabilities --------438.96 Cr427.68 Cr465.69 Cr710.20 Cr
Long Term Debt --------74.25 Cr44.92 Cr90.73 Cr160.95 Cr
Total Debt 188.00 Cr182.00 Cr192.00 Cr319.00 Cr231.00 Cr264.00 Cr182.00 Cr-128.45 Cr95.39 Cr157.14 Cr301.27 Cr
Total Equity 161.00 Cr187.00 Cr546.00 Cr558.00 Cr699.00 Cr710.00 Cr787.00 Cr-994.10 Cr1,282.70 Cr1,524.81 Cr1,874.47 Cr
Shares Outstanding --------1.28 Cr1.28 Cr1.28 Cr1.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 13.00 Cr45.00 Cr39.00 Cr11.00 Cr70.00 Cr57.00 Cr189.00 Cr-237.21 Cr261.18 Cr317.40 Cr346.68 Cr
Investing Cash Flow -14.00 Cr-20.00 Cr-42.00 Cr-116.00 Cr-77.00 Cr-49.00 Cr-84.00 Cr--61.50 Cr-149.69 Cr-298.16 Cr-423.73 Cr
Financing Cash Flow 1.00 Cr-24.00 Cr-0105.00 Cr12.00 Cr-5.00 Cr-114.00 Cr--135.80 Cr-69.28 Cr24.96 Cr20.98 Cr
Capital Expenditure -14.00 Cr-19.00 Cr-41.00 Cr-132.00 Cr-63.00 Cr-48.00 Cr-105.00 Cr--66.13 Cr-143.67 Cr-206.46 Cr-397.13 Cr
Free Cash Flow -1.00 Cr26.00 Cr-2.00 Cr-121.00 Cr7.00 Cr9.00 Cr84.00 Cr-171.08 Cr117.51 Cr110.94 Cr-50.45 Cr
Net Change in Cash 01.00 Cr-4.00 Cr-05.00 Cr3.00 Cr-9.00 Cr-39.92 Cr42.21 Cr44.21 Cr-56.08 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------47.1%51.6%47.7%51.0%
Operating Margin % 11.1%12.5%15.0%5.5%4.8%9.3%11.4%-20.2%26.9%18.6%25.4%
Net Margin % 3.4%5.3%8.1%2.3%2.4%2.1%8.6%-14.1%19.8%18.1%18.8%
ROE % 9.9%14.4%8.6%2.2%2.3%2.3%10.3%-16.4%23.4%17.1%19.4%
ROCE % --------20.5%29.0%15.6%22.1%

Shareholding Pattern

Insiders
37.74%
Institutions
28.13%
Public Float
45.18%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEULANDLAB

Google News Mon, 19 Oct 2026

NEULAND LABORATORIES LIMITED (NEULANDLAB-EQ.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1MRW5BXzE3ci1wUklfbTRHWDc3cmxnS3p1TXEyTmZzWlpmSjAxT2JDNU5BWTJRbElmS0FLNXY1MXNjVHI3SW9OdWZnQS15U2RQNjU2ZXB3RFhOR1J1aWtEelFmZTNhTXFhTHlRYlIwRnI?oc=5" target="_blank">NEULAND LABORATO…

Google News hu, 25 Jun 2026

NEULANDLAB Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9sVjI3Z3c4UWF5ZExlWkZDZENqMXhwTXlOQS14R3BPTlVhaE9ac1ljM2FKa3RSenNzUnVNMHNONW1fLXpsNVlCVGJOa1FVdDk3QWpnZ1lUWGNPaGFBSkVsY293bVVlbVRLeXhaVG05N0txZVRsbERuWkJaNEVPQQ?oc=5" target="_blan…

Google News Fri, 07 Aug 2026

Neuland Laboratories Limited Beat Revenue Forecasts By 23%: Here's What Analysts Are Forecasting Next - Webull

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9UVjBGaW5pS1R6TzNHb0h2NWFLNlVjM3dFcnFQUTlHWmt6RWtKcWtJQ1REOGJBa0tIcTl1SlJoRTk3SFF3LTQ5TC1nRi1VcS04NEc3Qy1INVo?oc=5" target="_blank">Neuland Laboratories Limited Beat Revenue Foreca…

Google News hu, 06 Aug 2026

Neuland Lab sizzles after Q1 PAT leaps over 10-fold to Rs 148 cr - Business Standard

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOUEM1c3JzSDd5MzN5OVFOU0d1emF6SWZPdFFsV0FxRjFUUjVrR0YzeDh1dDZZUE0wV0QyZmlDY0JIb2tENTQxQ1hPcVF1Qkc4SzE3enI4T1VOQzJnYl8tR3NUcUc5enRhVkNfRWhIQUp5WlBxQ1NWMG1GZllCWmF5d0RKelRGVHRoX0xvcz…

Google News Wed, 14 Oct 2026

NEULANDLAB Q2 2026 Earnings: 34.7% Revenue Growth Lifts EPS to ₹283.71 Despite Muted Stock Reaction - Margin Compression Risk - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNc1JpOENmRThlNHo2bUlQWEVITGFBMmxHeExjdUZfdTN3Rlh5TFNTOUJtTHRUNkpCUXNWaXJGNnBjcTlSNE5pTGZCOW11VTBjOUtmQWlkTFNlVWY2ejltMTk1bHZTUV92VElNMG1iTFpVWkR0SDFGRkQ0VDdIbllubDE4V08ySkZIbWdwOU…

Google News Wed, 14 Oct 2026

Neuland Laboratories: अमेरिकन FDA कडून मोठी दिलासादायक बातमी; युनिट ३ चा तपास पूर्ण! - Whalesbook

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxOckVSaWl0MFFzZGFBQjZkVjlnWmtINDd5Q1pmeDc4V3Y5WjB4R1NLN2NvN1kwV0NiWkFRN0VKT3B0UEZXS2lzbHpnYl9lTmVKQ1p5dEtxRFVLNTF3V09vdm4zcWhvT1l4NmVDYlViMU1xSF9mTHVUY2NiYUkxQnRRdHJPZlpfOFFvLWo4TW…

NEULANDLAB — Frequently Asked Questions

What is the current share price of Neuland Laboratories Limited (NEULANDLAB)?

As of 2026-10-23 04:58 IST, Neuland Laboratories Limited (NEULANDLAB) trades at ₹18,975.00 on NSE. Its 52-week range is ₹11,533.68 to ₹23,995.00.

What is the market capitalisation of NEULANDLAB?

Neuland Laboratories Limited (NEULANDLAB) has a market capitalisation of ₹24,344.71 Cr on NSE.

What is the P/E ratio of NEULANDLAB?

NEULANDLAB trades at a trailing price-to-earnings (P/E) ratio of 48.91. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 14.30.

Does NEULANDLAB pay a dividend?

Neuland Laboratories Limited (NEULANDLAB) currently offers a dividend yield of 0.16%.

What is the return on equity (ROE) of NEULANDLAB?

NEULANDLAB has a return on equity (ROE) of 19.42%. Its return on capital employed (ROCE) is 22.87%.

Is NEULANDLAB a good stock to buy?

This page provides a data-driven analysis of Neuland Laboratories Limited (NEULANDLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space